ArticleScientific reports2025
CTTN overexpression in HNSCC inhibits Anoikis-apoptosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Radiomics-based machine learning models decipher heterogeneity of anoikis-related molecular subtypes for prognostic stratification in head and neck squamous cell carcinoma.Translational cancer research · 2026Article
- Oral cancer in the era of precision medicine: molecular targets and technological innovations.Scientific reports · 2026Article
- Discovery and validation of a prognostic SPP1/PLAU signature in HPV-negative oropharyngeal squamous cell carcinoma.BMC medical genomics · 2026Article
- Targeting programmed cell death: a novel therapeutic paradigm for cancer based on mode-of-death classification.Apoptosis : an international journal on programmed cell death · 2026Review
- CFGSCDSA: Predicting circRNA-drug sensitivity associations based on collaborative feature learning and graph structure learning.PLoS computational biology · 2026Article
- An anoikis-related four-gene prognostic signature and functional characterization of ANXA5 in laryngeal squamous cell carcinoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Head and neck squamous cell carcinoma (HNSCC) is a highly prevalent and heterogeneous malignancy. Normal cells maintain their homeostasis through Anoikis, and tumor cells enhance their own invasion and migration by resisting Anoikis. The search for biomarkers of resistance to Anoikis in head and neck tumors could be helpful in evaluating the prognosis of patients as well as in finding therapeutic targets for HNSCC due to the lack of more definitive biomarkers in HNSCC. HNSCC cells were cultured in suspension, and HNSCC cells were found to undergo apoptosis after losing the support of ECM.LASSO-Cox regression analysis was applied to the TCGA-HNSC cohort to evaluate the prognostic value of apoptosis-associated genes, resulting in the construction of an apoptosis-related prognostic model (CTTN, PLAU, PLK1, BID, MAPK11, SPINK1, VEGFA, PIK3R2, CEACAM1, MAD2L1, SLCO1B3, TFDP1, SFRP1, SPP1, SPHK1). A risk score-based nomogram was developed to optimally predict survival in HNSCC patients. The role of the prognostic model gene CTTN in HNSCC apoptosis was validated via PI staining, IF, and WB. Knockdown of CTTN affected FAK expression levels in cells, reducing their anti-apoptotic capacity by impairing cytoskeletal formation. We validated CTTN function in HNSCC-PDOs. We analyzed the role of CTTN and its major subpopulations in pan-cancer and HNSCC. Silencing CTTN significantly suppressed growth in patient-derived organoids (PDOs) from HNSCC patients. CTTN was highly expressed in most tumors and predominantly detected in epithelial and fibroblast cells of HNSCC. This study established an association between ARGs and HNSCC. We developed a novel ARG-associated signature capable of predicting prognosis in HNSCC patients. Furthermore, we found that inhibiting the apoptosis-related gene CTTN suppresses the anti-apoptotic capacity of HNSCC. Results from HNSCC-PDOs suggest that CTTN may represent a key target for HNSCC invasion and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.